Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26157128 | 1.00 | DRD2 (0.41) | DRD2HRH3PABPC1CHRM3 | |
| SCHEMBL21771190 | 0.87 | GNAO1 (0.50) | CHRM3 | |
| SCHEMBL21771184 | 0.87 | GNAO1 (0.50) | CHRM3 | |
| SCHEMBL12714801 | 0.85 | DRD2 (0.47) | DRD2HRH3PABPC1 | |
| SCHEMBL23205046 | 0.84 | KDM1A (0.39) | — | |
| SCHEMBL21456150 | 0.84 | KDM1A (0.39) | — | |
| SCHEMBL21477159 | 0.84 | TP53 (0.36) | HRH3 | |
| SCHEMBL26157285 | 0.84 | SLC18A3 (0.37) | — | |
| SCHEMBL26157178 | 0.84 | HRH3 (0.39) | DRD2HRH3PABPC1CHRM3 | |
| SCHEMBL27097568 | 0.84 | HRH3 (0.41) | DRD2HRH3PABPC1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | DRD2 2944/4885HRH3 2096/4885PABPC1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.